Mark P. Stejbach — Chief Commercial Officer and Senior Vice President at Alkermes

Mr. Mark P. Stejbach has been the Chief Commercial Officer of Alkermes plc since February 29, 2012 and its Senior Vice President since February 2012. Mr. Stejbach is responsible for marketing, sales, managed care and trade channels, commercial analytics, patient services, new product planning and commercial strategy. Mr. Stejbach has more than 25 years of marketing, sales, finance and managed care experience from both Merck & Co. Inc. and Biogen Inc. Mr. Stejbach served as the Chief Commercial Officer and Vice President of Tengion, Inc., from June 2009 to December 31, 2011 and Chief Compliance Officer since June 2009. He served as Vice President of Marketing & Commercial Planning of Tengion Inc. from August 2008 to June 2009. Mr. Stejbach started his pharma career at Merck in 1987 and went on to lead marketing campaigns for Vasotec and Proscar. He served as a Vice President of Managed Care Marketing at Merck & Co., Inc., from 2005 to 2008. From 1994 to 1997, he worked for Biogen Inc. developing and executing the launch marketing plan for its highly successful first marketed product, Avonex, for multiple sclerosis. Mr. Stejbach then rejoined Merck in 1997 and since that time has held numerous senior leadership positions within Merck, including Senior Director roles in market development, specialty sales, marketing and investor relations and Vice President of Sales Services prior to his role as Vice President of Managed Care Marketing in Merck's United States Pharmaceutical division. He has been a Director of Flexion Therapeutics, Inc. since September 14, 2016. He was named as 2008 Emerging Pharma Leader by Pharmaceutical Executive magazine. Mr. Stejbach earned his MBA from The Wharton School, University of Pennsylvania and a BS degree in Mathematics from Virginia Tech.